Early Phase 1 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 80 years (inclusive), of any sex
• People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale called the ECOG performance status (scores 0, 1, or 2)
• People who have been diagnosed with multiple myeloma that has come back or stopped responding to treatment, and who have already received at least 3 previous rounds of treatment — including specific types of therapy known as proteasome inhibitors and immunomodulatory agents
• People of childbearing potential, and their partners, who agree to use highly effective contraception from the time of signing the consent form until 12 months after the last dose, and who agree not to donate eggs or sperm during that period
• People who voluntarily sign and date a written consent form agreeing to take part in the study
• People who are willing and able to follow the study schedule, attend appointments, and complete all required tests and follow-up visits

Who may not be able to join:

• Women who are pregnant or currently breastfeeding
• People who have had, or currently have, another type of cancer (in addition to multiple myeloma)
• People who test positive for HIV; have active hepatitis B virus infection above a certain level; have active or chronic hepatitis C; test positive for syphilis; or have an active cytomegalovirus (CMV) infection
• People who have an active infection that is not well controlled, based on the treating doctor's assessment
• People who have uncontrolled fluid build-up around the lungs, heart, or abdomen at the time of enrolment
• People with a history of severe allergic reactions such as anaphylactic shock; a known severe allergic reaction to the study treatment (IMV102) or any of its ingredients; or a known severe allergic reaction to a medication called tocilizumab
• People with serious mental health conditions
• People who have previously had a solid organ transplant (such as a kidney, liver, or heart transplant)
• People whom the study doctor assesses as unable or unwilling to follow the requirements of the study
• People with other serious or uncontrolled medical conditions that the study doctor considers would make participation unsafe or unsuitable

Important: Always verify eligibility with the trial site directly before applying.